Comparison of verona integron-borne metallo-β-lactamase (VIM) variants reveals differences in stability and inhibition profiles

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 3, 2016, Pages 1377-1384

  Makena, Anne ^a   Düzgün, Azer Ö ^b   Brem, Jürgen ^a   McDonough, Michael A ^a   Rydzik, Anna M ^a   Abboud, Martine I ^a   Saral, Ayşegül ^c   Çiçek, Ayşegül Č ^d   Sandalli, Cemal ^d   Schofield, Christopher J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b GUMUSHANE UNIVERSITY   (Turkey)

^c Faculty of Health Sciences   (Turkey)

^d RECEP TAYYIP ERDOGAN UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; BETA LACTAM; BETA LACTAMASE; CEFALOTIN; CEFOXITIN; CEFTAZIDIME; IMIPENEM; METALLO BETA LACTAMASE; PENICILLIN DERIVATIVE; BACTERIAL PROTEIN; BETA LACTAMASE INHIBITOR; BETA-LACTAMASE BLA(VIM-4), PSEUDOMONAS AERUGINOSA; BETA-LACTAMASE VIM-5, PSEUDOMONAS AERUGINOSA; RECOMBINANT PROTEIN; VIM-1 METALLO-BETA-LACTAMASE; VIM-2 BETA-LACTAMASE;

AMINO ACID SUBSTITUTION; ARTICLE; BIOCHEMICAL ANALYSIS; CATALYTIC EFFICIENCY; CIRCULAR DICHROISM; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; ELECTROSPRAY MASS SPECTROMETRY; ENANTIOMER; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STABILITY; HYDROLYSIS; INTEGRON; KINETIC PARAMETERS; KINETICS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MELTING POINT; MOLECULAR WEIGHT; NONHUMAN; NUCLEOPHILICITY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN SECONDARY STRUCTURE; STEADY STATE; SUBSTRATE CONCENTRATION; THERMOSTABILITY; CHEMISTRY; COMPARATIVE STUDY; GENETICS; METABOLISM; X RAY CRYSTALLOGRAPHY;

BACTERIAL PROTEINS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; CIRCULAR DICHROISM; CRYSTALLOGRAPHY, X-RAY; ENZYME STABILITY; INTEGRONS; RECOMBINANT PROTEINS;

EID: 84960155881     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01768-15     Document Type: Article

References (54)

1. Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention, Atlanta, GA.
2. Ambler RP. 1980. The structure of β-lactamases. Philos Trans R Soc Lond B 289:321-331. http://dx.doi.org/10.1098/rstb.1980.0049.
3. Page MI, Badarau A. 2008. The mechanisms of catalysis by metallo-β-lactamases. Bioinorg Chem Appl 2008:576297. http://dx.doi.org/10.1155/2008/576297.
4. Palzkill T. 2013. Metallo-β-lactamase structure and function. Ann N Y Acad Sci 1277:91-104. http://dx.doi.org/10.1111/j.1749-6632.2012.06796.x.
5. Diene SM, Rolain JM. 2014. Carbapenemase genes and genetic platforms in Gram-negative bacilli: Enterobacteriaceae, Pseudomonas and Acinetobacter species. Clin Microbiol Infect 20:831-838. http://dx.doi.org/10.1111/1469-0691.12655.
6. Miriagou V, Cornaglia G, Edelstein M, Galani I, Giske CG, Gniadkowski M, Malamou-Lada E, Martinez-Martinez L, Navarro F, Nordmann P, Peixe L, Pournaras S, Rossolini GM, Tsakris A, Vatopoulos A, Canton R. 2010. Acquired carbapenemases in Gram-negative bacterial pathogens: detection and surveillance issues. Clin Microbiol Infect 16:112-122. http://dx.doi.org/10.1111/j.1469-0691.2009.03116.x.
7. Nordmann P, Poirel L. 2002. Emerging carbapenemases in Gramnegative aerobes. Clin Microbiol Infect 8:321-331. http://dx.doi.org/10.1046/j.1469-0691.2002.00401.x.
8. Bebrone C. 2007. Metallo-β-lactamases (classification, activity, genetic organization, structure, zinc coordination) and their superfamily. Biochem Pharmacol 74:1686-1701. http://dx.doi.org/10.1016/j.bcp. 2007.05.021.
9. Daiyasu H, Osaka K, Ishino Y, Toh H. 2001. Expansion of the zinc metallo-hydrolase family of the β-lactamase fold. FEBS Lett 503:1-6. http://dx.doi.org/10.1016/S0014-5793 (01) 02686-2.
10. Garau G, Garcia-Saez I, Bebrone C, Anne C, Mercuri P, Galleni M, Frere JM, Dideberg O. 2004. Update of the standard numbering scheme for class B β-lactamases. Antimicrob Agents Chemother 48:2347-2349. http://dx.doi.org/10.1128/AAC.48.7.2347-2349.2004.
11. Zhang H, Hao Q. 2011. Crystal structure of NDM-1 reveals a common β-lactam hydrolysis mechanism. FASEB J 25:2574-2582. http://dx.doi.org/10.1096/fj.11-184036.
12. King DT, Worrall LJ, Gruninger R, Strynadka NC. 2012. New Delhi metallo-β-lactamase: structural insights into β-lactam recognition and inhibition. J Am Chem Soc 134:11362-11365. http://dx.doi.org/10.1021/ja303579d.
13. Mojica MF, Mahler SG, Bethel CR, Taracila MA, Kosmopoulou M, Papp-Wallace KM, Llarrull LI, Wilson BM, Marshall SH, Wallace CJ, Villegas MV, Harris ME, Vila AJ, Spencer J, Bonomo RA. 2015. Exploring the role of residue 228 in substrate and inhibitor recognition by VIM metallo-β-lactamases. Biochemistry 54:3183-3196. http://dx.doi.org/10.1021/acs.biochem.5b00106.
14. Franceschini N, Caravelli B, Docquier JD, Galleni M, Frere JM, Amicosante G, Rossolini GM. 2000. Purification and biochemical characterization of the VIM-1 metallo-β-lactamase. Antimicrob Agents Chemother 44:3003-3007. http://dx.doi.org/10.1128/AAC.44.11.3003-3007.2000.
15. Garcia-Saez I, Docquier JD, Rossolini GM, Dideberg O. 2008. The three-dimensional structure of VIM-2, a Zn-β-lactamase from Pseudomonas aeruginosa in its reduced and oxidised form. J Mol Biol 375:604-611. http://dx.doi.org/10.1016/j.jmb.2007.11.012.
16. aVIM-7, an evolutionarily distinct metallo-β-lactamase gene in a Pseudomonas aeruginosa isolate from the United States. Antimicrob Agents Chemother 48:329-332. http://dx.doi.org/10.1128/AAC.48.1.329-332.2004.
17. Kontou M, Pournaras S, Kristo I, Ikonomidis A, Maniatis AN, Stathopoulos C. 2007. Molecular cloning and biochemical characterization of VIM-12, a novel hybrid VIM-1/VIM-2 metallo-β-lactamase from a Klebsiella pneumoniae clinical isolate, reveal atypical substrate specificity. Biochemistry 46:13170-13178. http://dx.doi.org/10.1021/bi701258w.
18. Juan C, Beceiro A, Gutierrez O, Alberti S, Garau M, Perez JL, Bou G, Oliver A. 2008. Characterization of the new metallo-β-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. Antimicrob Agents Chemother 52:3589-3596. http://dx.doi.org/10.1128/AAC.00465-08.
19. Lassaux P, Traore DA, Loisel E, Favier A, Docquier JD, Sohier JS, Laurent C, Bebrone C, Frere JM, Ferrer JL, Galleni M. 2011. Biochemical and structural characterization of the subclass B1 metallo-β-lactamase VIM-4. Antimicrob Agents Chemother 55:1248-1255. http://dx.doi.org/10.1128/AAC.01486-09.
20. VIM, a new integron-borne metallo-β-lactamase gene from a Pseudomonas aeruginosa clinical isolate. Antimicrob Agents Chemother 43:1584-1590.
21. Poirel L, Naas T, Nicolas D, Collet L, Bellais S, Cavallo JD, Nordmann P. 2000. Characterization of VIM-2, a carbapenem-hydrolyzing metallo-β-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrob Agents Chemother 44:891-897. http://dx.doi.org/10.1128/AAC.44.4.891-897.2000.
22. VIM-2-containing integrons from Pseudomonas aeruginosa plasmids encoding the VIM-2 metallo-β-lactamase. FEMS Microbiol Lett 195:145-150. http://dx.doi.org/10.1111/j.1574-6968.2001.tb10512.x.
23. VIM-1 in a clinical strain of Pseudomonas aeruginosa. Antimicrob Agents Chemother 46:4026-4028. http://dx.doi.org/10.1128/AAC.46.12.4026-4028.2002.
24. Midilli K, Aygün G, Kuskucu M. 2003. A new variant of metallo-β-lactamase detected in a Klebsiella pneumoniae strain: VIM-5, abstr S-21, p 275. Abstr KLIMIK Congr, Istanbul, Turkey.
25. Bahar G, Mazzariol A, Koncan R, Mert A, Fontana R, Rossolini GM, Cornaglia G. 2004. Detection of VIM-5 metallo-β-lactamase in a Pseudomonas aeruginosa clinical isolate from Turkey. J Antimicrob Chemother 54:282-283. http://dx.doi.org/10.1093/jac/dkh321.
26. Gacar GG, Midilli K, Kolayli F, Ergen K, Gundes S, Hosoglu S, Karadenizli A, Vahaboglu H. 2005. Genetic and enzymatic properties of metallo-β-lactamase VIM-5 from a clinical isolate of Enterobacter cloacae. Antimicrob Agents Chemother 49:4400-4403. http://dx.doi.org/10.1128/AAC.49.10.4400-4403.2005.
27. Iraz M, Duzgun AO, Cicek AC, Bonnin RA, Ceylan A, Saral A, Nordmann P, Sandalli C. 2014. Characterization of novel VIM carbapenemase, VIM-38, and first detection of GES-5 carbapenem-hydrolyzing β-lactamases in Pseudomonas aeruginosa in Turkey. Diagn Microbiol Infect Dis 78:292-294. http://dx.doi.org/10.1016/j.diagmicrobio.2013.12.003.
28. Borgianni L, Vandenameele J, Matagne A, Bini L, Bonomo RA, Frere JM, Rossolini GM, Docquier JD. 2010. Mutational analysis of VIM-2 reveals an essential determinant for metallo-β-lactamase stability and folding. Antimicrob Agents Chemother 54:3197-3204. http://dx.doi.org/10.1128/AAC.01336-09.
29. Docquier JD, Lamotte-Brasseur J, Galleni M, Amicosante G, Frere JM, Rossolini GM. 2003. On functional and structural heterogeneity of VIMtype metallo-β-lactamases. J Antimicrob Chemother 51:257-266. http://dx.doi.org/10.1093/jac/dkg067.
30. Leiros HK, Edvardsen KS, Bjerga GE, Samuelsen O. 2015. Structural and biochemical characterization of VIM-26 shows that Leu224 has implications for the substrate specificity of VIM metallo-β-lactamases. FEBS J 282:1031-1042. http://dx.doi.org/10.1111/febs.13200.
31. Merino M, Perez-Llarena FJ, Kerff F, Poza M, Mallo S, Rumbo-Feal S, Beceiro A, Juan C, Oliver A, Bou G. 2010. Role of changes in the L3 loop of the active site in the evolution of enzymatic activity of VIM-type metallo-β-lactamases. J Antimicrob Chemother 65:1950-1954. http://dx.doi.org/10.1093/jac/dkq259.
32. Kupper MB, Herzog K, Bennink S, Schlomer P, Bogaerts P, Glupczynski Y, Fischer R, Bebrone C, Hoffmann KM. 2015. The three-dimensional structure of VIM-31, a metallo-β-lactamase from Enterobacter cloacae in its native and oxidized form. FEBS J 282:2352-2360. http://dx.doi.org/10.1111/febs.13283.
33. Leiros HK, Skagseth S, Edvardsen KS, Lorentzen MS, Bjerga GE, Leiros I, Samuelsen O. 2014. His224 alters the R2 drug binding site and Phe218 influences the catalytic efficiency of the metallo-β-lactamase VIM-7. Antimicrob Agents Chemother 58:4826-4836. http://dx.doi.org/10.1128/AAC.02735-13.
34. Makena A, Brem J, Pfeffer I, Geffen RE, Wilkins SE, Tarhonskaya H, Flashman E, Phee LM, Wareham DW, Schofield CJ. 2015. Biochemical characterization of New Delhi metallo-β-lactamase variants reveals differences in protein stability. J Antimicrob Chemother 70:463-469. http://dx.doi.org/10.1093/jac/dku403.
35. Savitsky P, Bray J, Cooper CD, Marsden BD, Mahajan P, Burgess-Brown NA, Gileadi O. 2010. High-throughput production of human proteins for crystallization: the SGC experience. J Struct Biol 172:3-13. http://dx.doi.org/10.1016/j.jsb.2010.06.008.
36. Van Berkel SS, Brem J, Rydzik AM, Salimraj R, Cain R, Verma A, Owens RJ, Fishwick CW, Spencer J, Schofield CJ. 2013. Assay platform for clinically relevant metallo-β-lactamases. J Med Chem 56:6945-6953. http://dx.doi.org/10.1021/jm400769b.
37. Makena A, Van Berkel SS, Lejeune C, Owens RJ, Verma A, Salimraj R, Spencer J, Brem J, Schofield CJ. 2013. Chromophore-linked substrate (CLS405): probing metallo-β-lactamase activity and inhibition. ChemMedChem 8:1923-1939. http://dx.doi.org/10.1002/cmdc.20130 0350.
38. Raussens V, Ruysschaert JM, Goormaghtigh E. 2003. Protein concentration is not an absolute prerequisite for the determination of secondary structure from circular dichroism spectra: a new scaling method. Anal Biochem 319:114-121. http://dx.doi.org/10.1016/S0003-2697 (03) 00285-9.
39. Whitmore L, Wallace BA. 2008. Protein secondary structure analyses from circular dichroism spectroscopy: methods and reference databases. Biopolymers 89:392-400. http://dx.doi.org/10.1002/bip. 20853.
40. Sreerama N, Woody RW. 2000. Estimation of protein secondary structure from circular dichroism spectra: comparison of CONTIN, SELCON, and CDSSTR methods with an expanded reference set. Anal Biochem 287:252-260. http://dx.doi.org/10.1006/abio.2000.4880.
41. Rydzik AM, Chowdhury R, Kochan GT, Williams ST, McDonough MA, Kawamura K, Schofield CJ. 2014. Modulating carnitine levels by targeting its biosynthesis-selective inhibition of γ-butyrobetaine hydroxylase. Chem Sci 5:1765-1771. http://dx.doi.org/10.1039/c4sc00020j.
42. Viswanatha T, Marrone L, Goodfellow V, Dmitrienko GI. 2008. Assays for β-lactamase activity and inhibition. Methods Mol Med 142:239-260. http://dx.doi.org/10.1007/978-1-59745-246-5-19.
43. Leung IK, Demetriades M, Hardy AP, Lejeune C, Smart TJ, Szollossi A, Kawamur A, Schofield CJ, Claridge TD. 2013. Reporter ligand NMR screening method for 2-oxoglutarate oxygenase inhibitors. J Med Chem 56:547-555. http://dx.doi.org/10.1021/jm301583m.
44. Kabsch W. 2010. Xds. Acta Crystallogr D Biol Crystallogr 66:125-132. http://dx.doi.org/10.1107/S0907444909047337.
45. Evans P. 2006. Scaling and assessment of data quality. Acta Crystallogr D Biol Crystallogr 62:72-82. http://dx.doi.org/10.1107/S0907444 905036693.
46. Winter G, Lobley CM, Prince SM. 2013. Decision making in xia2. Acta Crystallogr D Biol Crystallogr 69:1260-1273. http://dx.doi.org/10.1107/S0907444913015308.
47. Rossmann MG, Blow DM. 1962. The detection of sub-units within the crystallographic asymmetric unit. Acta Crystallogr 15:24-31. http://dx.doi.org/10.1107/S0365110X62000067.
48. Read RJ. 2001. Pushing the boundaries of molecular replacement with maximum likelihood. Acta Crystallogr D Biol Crystallogr 57:1373-1382. http://dx.doi.org/10.1107/S0907444901012471.
49. Adams PD, Gopal K, Grosse-Kunstleve RW, Hung LW, Ioerger TR, McCoy AJ, Moriarty NW, Pai RK, Read RJ, Romo TD, Sacchettini JC, Sauter NK, Storoni LC, Terwilliger TC. 2004. Recent developments in the PHENIX software for automated crystallographic structure determination. J Synchrotron Radiat 11:53-55. http://dx.doi.org/10.1107/S0909049503024130.
50. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. 2007. Phaser crystallographic software. J Appl Crystallogr 40:658-674. http://dx.doi.org/10.1107/S0021889807021206.
51. Lassaux P, Hamel M, Gulea M, Delbruck H, Mercuri PS, Horsfall L, Dehareng D, Kupper M, Frere JM, Hoffmann K, Galleni M, Bebrone C. 2010. Mercaptophosphonate compounds as broad-spectrum inhibitors of the metallo-β-lactamases. J Med Chem 53:4862-4876. http://dx.doi.org/10.1021/jm100213c.
52. Emsley P, Lohkamp B, Scott WG, Cowtan K. 2010. Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66:486-501. http://dx.doi.org/10.1107/S0907444910007493.
53. Aitha M, Marts AR, Bergstrom A, Moller AJ, Moritz L, Turner L, Nix JC, Bonomo RA, Page RC, Tierney DL, Crowder MW. 2014. Biochemical, mechanistic, and spectroscopic characterization of metallo-β-lactamase VIM-2. Biochemistry 53:7321-7331. http://dx.doi.org/10.1021/bi500916y.
54. Brem J, Van Berkel SS, Aik W, Rydzik AM, Avison MB, Pettinati I, Umland KD, Kawamura A, Spencer J, Claridge TD, McDonough MA, Schofield CJ. 2014. Rhodanine hydrolysis leads to potent thioenolate mediated metallo-β-lactamase inhibition. Nat Chem 6:1084-1090. http://dx.doi.org/10.1038/nchem.2110.